Загрузка...
Is Receptor-Interacting Protein Kinase 3 a Viable Therapeutic Target for Mycobacterium tuberculosis Infection?
The dwindling list of antimicrobial agents exhibiting broad efficacy against clinical strains of Mycobacterium tuberculosis (Mtb) has forced the medical community to redefine current approaches to the treatment of tuberculosis (TB). Host receptor-interacting protein kinase 3 (RIPK3) has been flagged...
Сохранить в:
| Опубликовано в: : | Front Immunol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5985376/ https://ncbi.nlm.nih.gov/pubmed/29892302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01178 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|